PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications

Success of review model for new molecular entities and novel biologics should bolster US FDA and industry's stance that Congress reauthorize the user fee program without tinkering with the negotiated agreement, which retains the 'Program' but builds in more flexibility.